Amyotrophic Lateral Sclerosis Treatment Market Size to Hit USD 436.17 Million by 2027 at 5.52% CAGR Reported by Brandessence Market Research

LONDON, March 30, 2023 /PRNewswire/ -- The Global Amyotrophic Lateral Sclerosis Treatment Market was worth USD 316.01 million in 2020 and is poised to amass a valuation of USD 436.17 million by 2027, witnessing a CAGR of 5.52% over the assessment timeline of 2022-2029.

Amyotrophic Lateral Sclerosis, also known as Lou Gehrig's disease, is a rare neurological disorder that leads to muscle weakening which in turn impacts the entire physical function of the patient. It mostly begins with weakness in limb, slurred speech, and muscle twitching. According to experts, sudden mutations in more than a dozen genes predominantly results in ALS. As of now there is no proven cure for this ailment, but certain drugs and therapies have been develop to reduce the symptoms and limit disease progression.

Get Sample of Report@ https://brandessenceresearch.com/downloadSample/PostId/1465

Global Amyotrophic Lateral Sclerosis Treatment Market Outlook (2022-2029)

The growing prevalence of neurological disorders, rising healthcare expenditure, and technological advancements in the field are primarily augmenting the outlook of this business sphere.

Alongside, surge in the geriatric population base, the booming medical research vertical, and rapidly evolving healthcare infrastructure across various regions are creating lucrative opportunities for this industry vertical to prosper.

Moreover, presence of favorable reimbursement scenario across numerous nations is aiding the expansion of this marketplace.

On the flipside, low availability of the drugs used to treat this disease due to its rare nature is hindering the remuneration scope of this market.     

Competitive Hierarchy

The prominent players defining the competitive terrain of the Global Amyotrophic Lateral Sclerosis Treatment Market are Mitsubishi Tanabe Pharma Corporation, Sun Pharmaceutical Industries Ltd., CORESTEM, Inc., BrainStorm Cell Limited, Amylyx Pharmaceuticals Inc., AB Science, Ionis Pharmaceuticals, Biohaven Pharmaceutical, Biogen, and Others.

Segmental Outlook

By Type

• Sporadic ALS
• Familial ALS

By Treatment

• Medication
• Riluzole
• Edaravone
• Nuedexta
• Physical Therapy
• Respiratory Therapy
• Speech Therapy
• Others

By End User